February 5, 2025
Hot News

Early intervention with iron delivered intravenously during pregnancy found safe and effective treatment for anemia

MyBlueDots01 mins
Anemia during pregnancy is a common occurrence and often due to iron deficiency. It is a global public health problem, affecting an estimated 37% of pregnant individuals, according to the World Health Organization. Iron deficiency anemia is associated with increased rates of pregnancy-related problems, such as going into labor prematurely, hemorrhaging and, in some cases, even death. For the infant, maternal iron deficiency also can have long-term implications on their overall health and development.
Read More

Biocytogen und Acepodia bündeln ihre Kräfte, um bispezifische Antikörper und Dual-Payload-ADCs zur Behandlung komplexer Tumore voranzutreiben

MyBlueDots01 mins
PEKING & ALAMEDA, Kalifornien. & TAIPEI–(BUSINESS WIRE)–Biocytogen (HKEX: 02315) und Acepodia (6976:TT) gaben heute eine bahnbrechende strategische Partnerschaft bekannt, um gemeinsam ein Programm für ein bispezifisches Antikörper-Wirkstoff-Konjugat (BsAD2C) mit zwei Nutzlasten zu bewerten. Diese Zusammenarbeit kombiniert die RenLite®-Plattform von Biocytogen mit der AD2C-Technologie (Antibody-Dual-Drugs Conjugation) von Acepodia, um einige der größten Herausforderungen in der Onkologie zu be
Read More

Castle Biosciences Announces Preliminary Unaudited Fourth Quarter and Full-Year 2024 Results

MyBlueDots01 mins
FRIENDSWOOD, Texas–(BUSINESS WIRE)–Castle Biosciences, Inc. (Nasdaq: CSTL), a company improving health through innovative tests that guide patient care, today announced certain unaudited preliminary performance results for the fourth quarter and year ended Dec. 31, 2024. “Our strong fourth quarter performance underscores continued momentum built throughout 2024, reflecting the strength of our growth initiatives and the dedication of our team,” said Derek Maetzold, president and chief executiv
Read More

Bayer Submits Supplemental New Drug Application to U.S. FDA Seeking New Indication for KERENDIA® (finerenone) in Patients with Heart Failure with Left Ventricular Ejection Fraction of ≥40%

MyBlueDots01 mins
WHIPPANY, N.J.–(BUSINESS WIRE)–Bayer today announced the submission of a supplemental new drug application (sNDA) to the U.S. Food and Drug Administration (FDA) for KERENDIA® (finerenone) for the treatment of patients with heart failure (HF) with a left ventricular ejection fraction (LVEF) of ≥40%. The submission is based on positive results from the Phase III FINEARTS-HF trial that showed finerenone achieved a statistically significant reduction of the composite of cardiovascular death and t
Read More

Study finds that community health workers were vital to Orange County’s COVID-19 response

MyBlueDots01 mins
Community health workers were found to be the unsung heroes of the health care system’s pandemic response, according to a study led by a team of public health researchers from the University of California, Irvine, and their community partners. Findings also show that current funding and reimbursement mechanisms remain inadequate to sustain their work.
Read More
Top